Symbols / RCEL Stock $4.12 +0.00% AVITA Medical, Inc.

Healthcare • Medical Devices • United States • NCM
RCEL (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Cary G. Vance
Exch · Country NCM · United States
Market Cap 126.80M
Enterprise Value 160.66M
Income -45.34M
Sales 72.35M
FCF (ttm) -18.31M
Book/sh -0.55
Cash/sh 0.46
Employees 226
Insider 10d —
IPO May 14, 2012
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -5.13
PEG —
P/S 1.75
P/B -7.56
P/C —
EV/EBITDA -4.33
EV/Sales 2.22
Quick Ratio 0.36
Current Ratio 0.47
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.56
EPS next Y -0.80
EPS Growth —
Revenue Growth 4.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-14
ROA -40.78%
ROE —
ROIC —
Gross Margin 81.36%
Oper. Margin -45.73%
Profit Margin -62.67%
Shs Outstand 30.78M
Shs Float 30.39M
Insider Own 1.47%
Instit Own 17.15%
Short Float 10.83%
Short Ratio 12.62
Short Interest 3.30M
52W High 7.12
vs 52W High -42.13%
52W Low 3.22
vs 52W Low 27.95%
Beta 1.86
Impl. Vol. 43.53%
Rel Volume 0.92
Avg Volume 237.00K
Volume 218.54K
Target (mean) $7.04
Tgt Median $5.87
Tgt Low $5.33
Tgt High $9.91
# Analysts 3
Recom Strong_buy
Prev Close $4.12
Price $4.12
Change 0.00%
About

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.04
Mean price target
2. Current target
$4.12
Latest analyst target
3. DCF / Fair value
$-10.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.12
Low
$5.33
High
$9.91
Mean
$7.04

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-15 up Lake Street Hold → Buy $6
2026-04-09 main D. Boral Capital Buy → Buy $10
2026-04-08 main D. Boral Capital Buy → Buy $10
2026-03-05 init Northland Capital Markets — → Outperform $10
2026-02-17 main D. Boral Capital Buy → Buy $10
2026-01-26 main D. Boral Capital Buy → Buy $10
2026-01-16 main Lake Street Hold → Hold $4
2026-01-15 main D. Boral Capital Buy → Buy $10
2025-11-20 up BTIG Sell → Neutral —
2025-11-07 main D. Boral Capital Buy → Buy $14
2025-10-17 down Lake Street Buy → Hold $4
2025-10-17 main D. Boral Capital Buy → Buy $14
2025-09-15 main D. Boral Capital Buy → Buy $14
2025-09-05 main D. Boral Capital Buy → Buy $14
2025-08-11 main Lake Street Buy → Buy $8
2025-08-08 main D. Boral Capital Buy → Buy $18
2025-06-10 main D. Boral Capital Buy → Buy $19
2025-06-06 main D. Boral Capital Buy → Buy $19
2025-04-10 main D. Boral Capital Buy → Buy $22
2025-04-04 main D. Boral Capital Buy → Buy $22
News
RSS: Latest RCEL news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
71.61
+11.45%
64.25
+28.14%
50.14
+45.68%
34.42
Operating Revenue
71.61
+11.45%
64.25
+28.14%
50.14
+45.68%
34.42
Cost Of Revenue
12.79
+40.69%
9.09
+16.89%
7.78
+28.79%
6.04
Reconciled Cost Of Revenue
12.79
+40.69%
9.09
+16.89%
7.78
+28.79%
6.04
Gross Profit
58.82
+6.63%
55.16
+30.20%
42.36
+49.27%
28.38
Operating Expense
101.35
-9.31%
111.75
+31.44%
85.02
+52.13%
55.88
Research And Development
20.84
+2.35%
20.36
-2.21%
20.82
+50.26%
13.86
Selling General And Administration
80.51
-11.90%
91.39
+39.26%
65.62
+45.05%
45.24
Selling And Marketing Expense
53.14
-8.69%
58.20
+56.06%
37.29
+70.18%
21.91
General And Administrative Expense
27.37
-17.54%
33.20
+17.16%
28.33
+21.45%
23.33
Other Gand A
27.37
-17.54%
33.20
+17.16%
28.33
+21.45%
23.33
Other Operating Expenses
—
—
-1.43
+55.58%
-3.21
Total Expenses
114.14
-5.54%
120.84
+30.22%
92.80
+49.85%
61.93
Operating Income
-42.53
+24.84%
-56.59
-32.68%
-42.66
-55.08%
-27.50
Total Operating Income As Reported
-42.53
+24.84%
-56.59
-32.68%
-42.66
-55.08%
-27.50
EBITDA
-41.23
+25.46%
-55.30
-64.89%
-33.54
-28.78%
-26.05
Normalized EBITDA
-41.23
+25.46%
-55.30
-64.89%
-33.54
-28.78%
-26.05
Reconciled Depreciation
2.35
+108.44%
1.13
+78.16%
0.63
+11.27%
0.57
EBIT
-43.57
+22.79%
-56.43
-65.14%
-34.17
-28.40%
-26.61
Net Income
-48.59
+21.44%
-61.84
-74.80%
-35.38
-32.69%
-26.66
Pretax Income
-48.58
+21.39%
-61.79
-74.97%
-35.31
-32.62%
-26.63
Net Non Operating Interest Income Expense
-5.00
+6.66%
-5.36
-369.03%
-1.14
-7043.75%
-0.02
Interest Expense Non Operating
5.00
-6.66%
5.36
+369.03%
1.14
+7043.75%
0.02
Net Interest Income
-5.00
+6.66%
-5.36
-369.03%
-1.14
-7043.75%
-0.02
Interest Expense
5.00
-6.66%
5.36
+369.03%
1.14
+7043.75%
0.02
Other Income Expense
-1.04
-736.81%
0.16
-98.08%
8.48
+851.01%
0.89
Other Non Operating Income Expenses
-1.04
-736.81%
0.16
-98.08%
8.48
+851.01%
0.89
Tax Provision
0.01
-79.63%
0.05
-18.18%
0.07
+83.33%
0.04
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-48.59
+21.44%
-61.84
-74.80%
-35.38
-32.69%
-26.66
Net Income From Continuing Operation Net Minority Interest
-48.59
+21.44%
-61.84
-74.80%
-35.38
-32.69%
-26.66
Net Income From Continuing And Discontinued Operation
-48.59
+21.44%
-61.84
-74.80%
-35.38
-32.69%
-26.66
Net Income Continuous Operations
-48.59
+21.44%
-61.84
-74.80%
-35.38
-32.69%
-26.66
Normalized Income
-48.59
+21.44%
-61.84
-74.80%
-35.38
-32.69%
-26.66
Net Income Common Stockholders
-48.59
+21.44%
-61.84
-74.80%
-35.38
-32.69%
-26.66
Diluted EPS
-1.74
+27.20%
-2.39
-70.71%
-1.40
-30.84%
-1.07
Basic EPS
-1.74
+27.20%
-2.39
-70.71%
-1.40
-30.84%
-1.07
Basic Average Shares
27.86
+7.64%
25.88
+2.18%
25.33
+1.32%
25.00
Diluted Average Shares
27.86
+7.64%
25.88
+2.18%
25.33
+1.32%
25.00
Diluted NI Availto Com Stockholders
-48.59
+21.44%
-61.84
-74.80%
-35.38
-32.69%
-26.66
Line Item Trend 2023-12-31
Total Assets
111.64
Current Assets
104.01
Cash Cash Equivalents And Short Term Investments
89.06
Cash And Cash Equivalents
22.12
Other Short Term Investments
66.94
Receivables
7.92
Accounts Receivable
7.66
Gross Accounts Receivable
55.66
Allowance For Doubtful Accounts Receivable
-48.00
Other Receivables
0.26
Inventory
5.60
Raw Materials
3.68
Work In Process
0.88
Finished Goods
1.03
Prepaid Assets
1.41
Restricted Cash
—
Other Current Assets
1.43
Total Non Current Assets
7.63
Net PPE
4.32
Gross PPE
6.75
Accumulated Depreciation
-2.43
Properties
0.00
Machinery Furniture Equipment
2.65
Construction In Progress
0.09
Other Properties
3.65
Leases
0.37
Goodwill And Other Intangible Assets
0.49
Other Intangible Assets
0.49
Investments And Advances
0.00
Other Investments
—
Non Current Deferred Assets
—
Non Current Prepaid Assets
0.30
Other Non Current Assets
2.83
Total Liabilities Net Minority Interest
62.58
Current Liabilities
13.20
Payables And Accrued Expenses
11.77
Payables
3.79
Accounts Payable
3.79
Current Accrued Expenses
7.97
Current Debt And Capital Lease Obligation
0.90
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
0.90
Current Deferred Liabilities
0.17
Current Deferred Revenue
0.03
Other Current Liabilities
0.37
Total Non Current Liabilities Net Minority Interest
49.38
Long Term Debt And Capital Lease Obligation
41.51
Long Term Debt
39.81
Long Term Capital Lease Obligation
1.70
Defined Pension Benefit
—
Non Current Deferred Liabilities
4.02
Non Current Deferred Revenue
0.36
Other Non Current Liabilities
—
Preferred Securities Outside Stock Equity
0.69
Stockholders Equity
49.06
Common Stock Equity
49.06
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
25.68
Ordinary Shares Number
25.68
Treasury Shares Number
0.00
Additional Paid In Capital
350.04
Retained Earnings
-297.97
Gains Losses Not Affecting Retained Earnings
-1.89
Other Equity Adjustments
-1.89
Total Equity Gross Minority Interest
49.06
Total Capitalization
88.87
Working Capital
90.81
Invested Capital
88.87
Total Debt
42.41
Net Debt
17.69
Capital Lease Obligations
2.60
Net Tangible Assets
48.57
Tangible Book Value
48.57
Available For Sale Securities
—
Derivative Product Liabilities
3.16
Investmentin Financial Assets
0.00
Other Equity Interest
-1.13
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-31.20
+36.26%
-48.94
-28.75%
-38.01
-99.11%
-19.09
Cash Flow From Continuing Operating Activities
-31.20
+36.26%
-48.94
-28.75%
-38.01
-99.11%
-19.09
Net Income From Continuing Operations
-48.59
+21.44%
-61.84
-74.80%
-35.38
-32.69%
-26.66
Depreciation Amortization Depletion
2.35
+108.44%
1.13
+78.16%
0.63
+11.27%
0.57
Depreciation And Amortization
2.35
+108.44%
1.13
+78.16%
0.63
+11.27%
0.57
Other Non Cash Items
3.16
-14.75%
3.71
-19.48%
4.61
+284.39%
1.20
Pension And Employee Benefit Expense
—
—
0.86
+2152.63%
0.04
Stock Based Compensation
9.52
-29.47%
13.50
+60.97%
8.38
+19.81%
7.00
Provisionand Write Offof Assets
-0.01
-143.48%
0.02
-4.17%
0.02
+580.00%
-0.01
Asset Impairment Charge
0.81
+66.32%
0.49
+120.36%
0.22
-41.07%
0.38
Deferred Tax
—
—
—
—
Deferred Income Tax
—
—
—
—
Operating Gains Losses
-1.57
-474.64%
0.42
+104.89%
-8.54
-10315.85%
-0.08
Gain Loss On Investment Securities
-2.19
-898.91%
0.27
-63.47%
0.75
—
Net Foreign Currency Exchange Gain Loss
0.02
-19.05%
0.02
+100.22%
-9.38
-10932.94%
-0.09
Gain Loss On Sale Of PPE
0.61
+392.68%
0.12
+41.38%
0.09
+2800.00%
0.00
Change In Working Capital
3.44
+173.51%
-4.68
+28.84%
-6.57
-449.67%
-1.20
Change In Receivables
3.63
+187.65%
-4.14
-25.45%
-3.30
-235.43%
-0.98
Changes In Account Receivables
3.63
+187.65%
-4.14
+0.65%
-4.17
-956.20%
-0.40
Change In Inventory
-0.47
+78.33%
-2.16
+41.51%
-3.69
-895.42%
-0.37
Change In Prepaid Assets
0.77
+306.47%
-0.37
+17.74%
-0.45
-23.22%
-0.37
Change In Payables And Accrued Expense
0.11
-96.20%
2.82
+30.75%
2.16
+38.74%
1.55
Change In Accrued Expense
-2.64
-206.41%
2.48
+84.04%
1.35
+5.90%
1.27
Change In Payable
2.75
+707.35%
0.34
-57.97%
0.81
+186.88%
0.28
Change In Account Payable
2.75
+707.35%
0.34
-57.97%
0.81
+186.88%
0.28
Change In Other Working Capital
0.05
-89.18%
0.42
+4.68%
0.41
-45.14%
0.74
Change In Other Current Assets
0.34
+173.81%
-0.46
+62.77%
-1.24
-36.98%
-0.91
Change In Other Current Liabilities
-0.99
-25.77%
-0.78
-75.39%
-0.45
+48.14%
-0.86
Investing Cash Flow
12.45
-66.67%
37.36
+2225.02%
1.61
+108.31%
-19.33
Cash Flow From Continuing Investing Activities
12.45
-66.67%
37.36
+2225.02%
1.61
+108.31%
-19.33
Net PPE Purchase And Sale
-1.00
+89.04%
-9.17
-564.08%
-1.38
-205.53%
-0.45
Purchase Of PPE
-1.00
+89.04%
-9.17
-564.08%
-1.38
-205.53%
-0.45
Capital Expenditure
-1.74
+81.37%
-9.33
-544.99%
-1.45
-175.62%
-0.53
Capital Expenditure Reported
-0.64
0.00
—
—
Net Investment Purchase And Sale
14.19
-69.61%
46.70
+1429.01%
3.05
+116.24%
-18.81
Purchase Of Investment
-13.31
+45.69%
-24.50
+68.89%
-78.76
-5.91%
-74.36
Sale Of Investment
27.50
-61.38%
71.20
-12.97%
81.81
+47.26%
55.55
Net Intangibles Purchase And Sale
-0.10
+38.89%
-0.16
-145.45%
-0.07
+9.59%
-0.07
Purchase Of Intangibles
-0.10
+38.89%
-0.16
-145.45%
-0.07
+9.59%
-0.07
Financing Cash Flow
14.94
+325.77%
3.51
-91.31%
40.37
+4386.00%
0.90
Cash Flow From Continuing Financing Activities
14.94
+325.77%
3.51
-91.31%
40.37
+4386.00%
0.90
Net Issuance Payments Of Debt
—
0.00
-100.00%
38.76
0.00
Issuance Of Debt
—
0.00
-100.00%
38.76
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Issuance
—
0.00
-100.00%
38.76
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
0.00
-100.00%
38.76
0.00
Net Common Stock Issuance
14.79
0.00
—
0.00
Proceeds From Stock Option Exercised
1.20
-65.74%
3.51
+117.62%
1.61
+79.11%
0.90
Net Other Financing Charges
-1.06
—
—
—
Changes In Cash
-3.81
+52.81%
-8.07
-303.22%
3.97
+110.58%
-37.52
Effect Of Exchange Rate Changes
—
0.00
+100.00%
-0.02
+38.46%
-0.03
Beginning Cash Position
14.05
-36.48%
22.12
+21.77%
18.16
-67.40%
55.71
End Cash Position
10.24
-27.10%
14.05
-36.48%
22.12
+21.77%
18.16
Free Cash Flow
-32.93
+43.48%
-58.27
-47.68%
-39.46
-101.16%
-19.61
Interest Paid Supplemental Data
—
5.36
+368.85%
1.14
+7520.00%
0.01
Income Tax Paid Supplemental Data
—
0.04
-6.82%
0.04
+158.82%
0.02
Amortization Of Securities
-0.31
+81.60%
-1.67
-21.22%
-1.38
-391.46%
-0.28
Common Stock Issuance
14.79
0.00
—
0.00
Issuance Of Capital Stock
14.79
0.00
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category